eli lilly glp-1 - Search News

News

Eli Lilly, GLP-1

Eli Lilly says new GLP-1 weight loss pill could reach market in 2026

Drugmaker Eli Lilly says after successful results in a phase 3 clinical trial, it expects to submit a GLP-1 weight loss pill for FDA approval by the end of the year. The pill does not produce the same amount of weight loss as injections,

CNN on MSN · 16h

Experimental GLP-1 pill helped people with obesity lose weight, Eli Lilly says

In the first Phase 3 trial of its once-daily oral GLP-1 pill in people with obesity, drugmaker Eli Lilly said Thursday that it helped people lower their weight by an average of 12% after 72 weeks.

USA TODAY on MSN · 2h

Could GPL-1 weight loss soon come in pill form? What we know

In a clinical trial, the company's weight loss pill resulted in a nearly 12% weight loss at 72 weeks for participants who took the highest dose of the medication. On average, participants lost 7.8% to 12.4% of their body weight, and 40% of people on the highest dose lost more than 15%, Eli Lilly reported.

ABC112h

Daily oral GLP-1 pill could be just as effective as weekly shots: Drugmaker

Drugmaker Eli Lilly says their oral, daily GLP-1 pill, orforglipron, may offer similar weight loss results as weekly GLP-1 ...

Fierce Biotech16h

Lilly's oral GLP-1 data 'as good as it gets' at 12% weight loss, exec says

As other pharmas drop next-gen obesity assets, Eli Lilly’s experimental oral GLP-1 has prompted weight loss up to ...

15hon MSN

Eli Lilly beats earnings for second quarter on strong GLP-1 sales, but stock dives on GLP-1 pill trial results

Eli Lilly (LLY) reported better than expected earnings for the second quarter Thursday. But disappointing results of its much ...

1don MSN

Can Eli Lilly keep its GLP-1 crown? Q2 earnings will tell

Eli Lilly (NYSE:LLY) is set to report Q2 earnings on Thursday, August 7, before the market opens, with Wall Street closely ...

Devdiscourse13h

Eli Lilly's GLP-1 Pill: A Diminished Competitor in the Obesity Drug Race

Eli Lilly's experimental GLP-1 pill showed a 12.4% body weight reduction, less than Novo Nordisk's injectable Wegovy in a ...

Fierce Pharma1d

Novo's outgoing CEO prepares to hand off business as sales threats from Lilly, GLP-1 compounders persist

On the one hand, the company is struggling to stay competitive with its chief rival Eli Lilly, and on the other, compounders ...

10hon MSN

Eli Lilly raises 2025 revenue guidance to $60B-$62B while expanding GLP-1 pipeline and production

Q2 2025 Management View CEO David A. Ricks highlighted a strong quarter, stating, "Q2 was a strong quarter. We delivered robust revenue growth, shared top line clinical data from multiple Phase III ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results